Clinical trials for Lymphoma
98 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lymphoma
#NCT06806033
#2024-516791-15-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Indolent transformed lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Allogeneic stem cell transplant
4 recruiting sites
Hoffmann-La Roche
Phase 2
Lymphoma
Brain tumors / Central nervous system tumors
#NCT07015242
#2025-521144-38-00
Required histologic types
B cell lymphoma
Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma
Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T
Allogeneic stem cell transplant
12 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy
Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT05139017
#2022-502646-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Car-T
Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2
Lymphoma
#NCT04984837
#2024-513252-15-00
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
1 recruiting site
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
Brain tumors / Central nervous system tumors
#NCT03328078
#2024-513312-95-00
Required histologic types
B cell lymphoma
Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma
Primary CNS lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Curis, Inc.
Phase 2
Lymphoma
#NCT05463263
Required histologic types
B cell lymphoma
T cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Step Pharma, SAS
Phase 2
Lymphoma
#NCT06271057
#2023-506705-20-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Primary mediastinal lymphoma
Indolent transformed lymphoma
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)